Skip to Content

Media

FAQS

Do you want to know something about Almirall?
These are the questions people most often ask of us.

faqs
MEDIA CONTACTS

Cohn & Wolfe
Tel: +34 91 531 50 97
Contact: Adriana Ibargüen

Almirall Media Relations
Tel: +34 93 291 30 00
Contact: Corporate Communications

Contact us

Request further information about Almirall

Contact us

News

24-03-2017

Almirall and Sun Pharma Announce Regulatory Filing of Tildrakizumab in Europe

Barcelona, SPAIN and Mumbai, INDIA, March 24, 2017: Almirall S.L, (Spanish Stock Exchange ticker: ALM, "Almirall") an ...

16-03-2017

Almirall and Symatese enter into a global strategic collaboration for the development and commercialization of products in the Aesthetics field

Almirall S.A., a global pharmaceutical company based in Barcelona, and Symatese, a leading developer and manufacturer ...

07-03-2017

Data from Tildrakizumab Clinical Development Program Presented at the 2017 American Academy of Dermatology Meeting

Barcelona, Spain, March 7, 2017 – Almirall S.L (Spanish Stock Exchange ticker: ALM) and Sun Pharmaceutical Industries Lt ...

27-02-2017

Almirall Full-Year 2016 results: Strong Dermatology results and promising pipeline

Barcelona, 27th February, 2017.- Almirall, the global pharmaceutical company based in Barcelona, has posted its full- ...